iRhythm Technologies announces board changes as two directors retire

SAN FRANCISCO - Digital health company iRhythm Technologies, Inc. (NASDAQ:IRTC) announced Monday the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, M.D., effective July 7, 2025.

The company simultaneously appointed Karen McGinnis and Kevin O’Boyle to its board of directors. Both new directors will serve on the company’s Audit Committee, with O’Boyle also joining the Nominating & Governance Committee.

Rubash, who joined in 2016 before the company’s IPO, brought financial and strategic expertise from high-growth technology companies. Snyderman, a board member since 2017, contributed clinical expertise during the company’s early development of digital health solutions.

"We are profoundly grateful to Mark and Ralph for their service, wisdom, and steadfast leadership during the better part of a decade," said Abhi Talwalkar, Chairman of the Board of Directors, according to the company’s press release.

McGinnis brings over 30 years of executive experience across biotechnology and technology industries, most recently serving as Chief Accounting Officer at Illumina, Inc. (NASDAQ:ILMN) from 2017 to 2021. She currently serves on the boards of Alphatec Holdings (NASDAQ:ATEC) and Absci Corporation (NASDAQ:ABSI). According to InvestingPro data, Absci has shown strong momentum with a 7.78% return over the past week and maintains a healthy balance sheet with more cash than debt. The company is scheduled to report its next earnings on August 19, 2025.

O’Boyle’s background includes executive leadership as CFO at NuVasive, where he helped grow the company’s market capitalization from $100 million to $2 billion. He currently serves as Audit Committee Chair at Outset Medical (NASDAQ:OM) and Carlsmed.

iRhythm Technologies specializes in digital healthcare solutions focused on cardiac monitoring and digital health innovation. For deeper insights into board member impacts on company performance and comprehensive financial analysis, InvestingPro offers detailed research reports covering 1,400+ US stocks, transforming complex Wall Street data into actionable intelligence for smarter investing decisions.

In other recent news, Absci Corporation reported its Q1 2025 earnings, revealing a revenue of $1.2 million and an increase in research and development expenses to $16.4 million. The company also noted an increase in cash reserves to $134 million, which extends its cash runway into 2027. Absci has initiated its first-in-human clinical trial for ABS-101, marking its transition to a clinical-stage biotech company. Morgan Stanley has initiated coverage on Absci with an Overweight rating, citing the potential for a value inflection point with ABS-101, which is expected to deliver Phase 1 interim data in the second half of 2025. The company is in discussions with three biopharma companies to partner on ABS-101, potentially extending its cash runway further. Additionally, Absci announced the appointment of Mary Szela to its Board of Directors. Szela brings extensive commercial and clinical leadership experience, which could support Absci’s ongoing development of AI-designed therapeutics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.